Latest Headlines

81. Charles River Laboratories And Autobahn Labs Announce Collaborative Program To Accelerate Academic Drug Discovery 7/24/2024

    Charles River Laboratories International, Inc. and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn’s growing pipeline of early-stage, preclinical therapeutics’ programs.

82. Defence Therapeutics Granted Cnri-H From The Canadian Nuclear Laboratories To Accelerate The Development Of Its Radio-Immuno-Conjugates Program 7/24/2024

    Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its Canadian Nuclear Research Initiative Health (“CNRI-H”) Program application was retained and approved by the Canadian Nuclear Laboratories (“CNL”) to accelerate Defence’s radio-immuno-conjugates project.

83. TIXiMED Receives IND Approval From The FDA For Its Novel Oral Antidiabetic, TIX100 7/23/2024

    TIXiMED, Inc. (https://tiximed.com), a clinical stage pharmaceutical company based on the breakthrough discovery that TXNIP plays an important role in the development and progression of diabetes, obtained Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA) for its oral type 1 diabetes drug, the specific TXNIP inhibitor, TIX100.

84. Waters New Rapid Screening-DSC Enables Up To 24x Faster Thermal Stability Testing At Ultra-Low Sample Volumes For Antibody Drugs 7/23/2024

    Waters Corporation (NYSE: WAT) announced today the global release of the TA Instruments™ Rapid Screening-Differential Scanning Calorimeter (TA Instruments RS-DSC), designed for biopharmaceutical developers.

85. IASO Bio Receives U.S. FDA Approval Of Investigational New Drug Application For Equecabtagene Autoleucel For Multiple Sclerosis 7/23/2024

    IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, announced that the investigational new drug (IND) application for the independently developed fully human anti-BCMA chimeric antigen receptor autologous T cell injection (Equecabtagene Autoleucel, Eque-cel) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS).

86. SciSparc: MitoCareX Confirms Potential Significant Role Of Its Drug Target In Non-Small Cell Lung Cancer 7/22/2024

    SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, has validated the potential significant involvement of its target SLC25 carrier protein, using Non-Small Cell Lung Cancer (“NSCLC”) cells with diverse genetic backgrounds.

87. Zymeworks Announces FDA Clearance Of Investigational New Drug Application For ZW191, A Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate 7/22/2024

    Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW191, the Company’s novel folate receptor-⍺ (FR⍺) targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (ADC).

88. Apollo Therapeutics And Oxford University Enter Into Drug Discovery And Development Collaboration 7/22/2024

    The University of Oxford and Apollo Therapeutics, a portfolio biopharmaceutical company, announce the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford.

89. Funding Boosts Endometriosis Drug Discovery Efforts 7/19/2024

    A key receptor is being targeted using robotic high-throughput screening at the National Drug Discovery Centre (NDDC) to fast-track new treatments for endometriosis.

90. Irish Scientists Pinpoint New Drug Target For RSV 7/18/2024

    The scientists have discovered how the dangerous Respiratory Syncytial Virus (RSV) defuses our immune response and, in doing so, have pinpointed an exciting new target for drug developers.